PGNY vs. AGL, SHC, MRUS, GDRX, CERT, NARI, BHC, MLTX, CLDX, and FTRE
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include agilon health (AGL), Sotera Health (SHC), Merus (MRUS), GoodRx (GDRX), Certara (CERT), Inari Medical (NARI), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), Celldex Therapeutics (CLDX), and Fortrea (FTRE). These companies are all part of the "medical" sector.
Progyny (NASDAQ:PGNY) and agilon health (NYSE:AGL) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
Progyny presently has a consensus price target of $43.11, suggesting a potential upside of 53.47%. agilon health has a consensus price target of $9.32, suggesting a potential upside of 72.30%. Given agilon health's higher probable upside, analysts plainly believe agilon health is more favorable than Progyny.
In the previous week, Progyny had 13 more articles in the media than agilon health. MarketBeat recorded 26 mentions for Progyny and 13 mentions for agilon health. Progyny's average media sentiment score of 0.11 beat agilon health's score of 0.06 indicating that Progyny is being referred to more favorably in the media.
94.9% of Progyny shares are owned by institutional investors. 12.3% of Progyny shares are owned by insiders. Comparatively, 3.2% of agilon health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Progyny has higher earnings, but lower revenue than agilon health. agilon health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Progyny has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, agilon health has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Progyny received 38 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 75.00% of users gave Progyny an outperform vote while only 52.69% of users gave agilon health an outperform vote.
Progyny has a net margin of 5.53% compared to agilon health's net margin of -5.67%. Progyny's return on equity of 11.61% beat agilon health's return on equity.
Summary
Progyny beats agilon health on 16 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
